Results 181 to 190 of about 3,283 (198)

Faricimab-Associated Intraocular Inflammation with Features of Herpes Simplex Virus.

American journal of ophthalmology-glaucoma
OBJECTIVE Faricimab-associated intraocular inflammation (IOI) is an emerging concern. We aimed to investigate clinical features, management, and outcomes of severe IOI following faricimab therapy, with particular attention to cases displaying features ...
I. Janmohamed, M. Salam, Omer Jamall, Mohamed Elgharably, Noha Ghoz, Aishwarya Amarnath, K. Theodoraki, Goncalo Almeida   +7 more
semanticscholar   +1 more source

Real World One-Year Outcomes of Treatment Intensive Neovascular Age Related Macular Degeneration switched to Faricimab.

Ophthalmology Retina
PURPOSE To report one-year anatomical and functional real-world outcomes of treatment intensive neovascular age related macular degeneration (nAMD) patients switched to faricimab DESIGN: Retrospective multi-centre cohort study SUBJECTS: Consecutive nAMD ...
Sing Yue Sim, Evangelia Chalkiadaki, Georgios Koutsocheras, L. Nicholson, S. Sivaprasad, Praveen J. Patel, Senthil Selvam, Bishwanath Pal, P. Keane, Bhairavi Bhatia, Robin D. Hamilton   +10 more
semanticscholar   +1 more source

Outcomes of Intravitreal Aflibercept 8 mg in Eyes With Neovascular Age-Related Macular Degeneration Previously Treated With Faricimab.

Ophthalmic Surgery Lasers and Imaging Retina
BACKGROUND AND OBJECTIVE To assess the efficacy of intravitreal aflibercept 8 mg in treating neovascular age-related macular degeneration (nAMD) in patients previously treated with faricimab.
Bita Momenaei, Yoshihiro Yonekawa, Paige Abril, Rachel McCullough, Ashkan M. Abbey   +4 more
semanticscholar   +1 more source

Real-World Outcomes After Switch From Aflibercept to Faricimab in Eyes With Diabetic Macular Edema

Investigative Ophthalmology and Visual Science
Purpose To assess the anatomic and functional outcomes in eyes with diabetic macular edema (DME) switched from intravitreal aflibercept to faricimab in a real-world setting. Methods Retrospective, interventional consecutive case series. Patients with DME
K. Huber, H. Stino, I. Steiner, Philipp Fuchs, Felix Goldbach, Julia Mai, B. Gerendas, K. Kriechbaum, Ursula Schmidt-Erfurth, A. Pollreisz   +9 more
semanticscholar   +1 more source

Faricimab: Transforming the Future of Macular Diseases Treatment - A Comprehensive Review of Clinical Studies

Drug Design, Development and Therapy, 2023
Winfried Amoaku, Georgios D Panos, Matteo Ripa   +2 more
exaly  

Spotlight on Faricimab in the Treatment of Wet Age-Related Macular Degeneration: Design, Development and Place in Therapy

Drug Design, Development and Therapy, 2022
Paul Sternberg, Jr.
exaly  

Intravitreal faricimab for neovascular age-related macular degeneration previously treated with traditional anti-VEGF compounds: a real-world prospective study

Graefe's Archive for Clinical and Experimental Ophthalmology, 2023
Moreno Menghini, Gabriela Grimaldi
exaly  

Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-Year subgroup analysis of the TENAYA and LUCERNE trials

Graefe's Archive for Clinical and Experimental Ophthalmology, 2023
Kanji Takahashi, Chui Ming Gemmy Cheung, Aachal Kotecha   +2 more
exaly  

Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration

Graefe's Archive for Clinical and Experimental Ophthalmology, 2023
Keiko Kataoka, Masashi Ogasawara, Nozomu Hashiya   +2 more
exaly  

Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial

Japanese Journal of Ophthalmology, 2023
Masahiko Shimura, Geeta Menon, Roberto Gallego-Pinazo   +2 more
exaly